Merck KGaA (XTRA:MRK) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

MRK Stoklara Genel Bakış

Merck KGaA, Almanya'da bir bilim ve teknoloji şirketi olarak faaliyet göstermektedir.

MRK temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	2/6
Finansal Sağlık	6/6
Temettüler	4/6

Ödüller

Trading at 49.8% below our estimate of its fair value

Earnings are forecast to grow 11.86% per year

Risk Analizi

Risk kontrollerimizden MRK için herhangi bir risk tespit edilmedi.

Merck KGaA Rakipler

Dermapharm Holding

XTRA:DMP

€1.9b

PharmaSGP Holding

XTRA:PSG

€251.8m

GSK

LSE:GSK

UK£62.1b

Chugai Pharmaceutical

TSE:4519

JP¥11.6t

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Merck KGaA
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€156.40
52 Haftanın En Yüksek Seviyesi	€177.00
52 Haftanın En Düşük Seviyesi	€134.30
Beta	0.71
11 Aylık Değişim	-11.06%
3 Aylık Değişim	3.41%
1 Yıllık Değişim	1.43%
33 Yıllık Değişim	-16.09%
5 Yıllık Değişim	52.88%
Halka arzdan bu yana değişim	908.44%

Son Haberler & Güncellemeler

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Sep 05

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Jul 24

Recent updates

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

Mar 26

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Mar 05

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Feb 14

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Dec 12

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Nov 09

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Aug 15

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

May 17

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Mar 29

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Jan 13

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

Oct 15

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Sep 19

MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Seems To Use Debt Quite Sensibly

Jul 11

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 21

Hissedar Getirileri

	MRK	DE Pharmaceuticals	DE Pazar
7D	0.3%	1.7%	1.8%
1Y	1.4%	-11.1%	13.8%

Getiri vs. Endüstri: MRK exceeded the German Pharmaceuticals industry which returned -11.5% over the past year.

Getiri vs Piyasa: MRK underperformed the German Market which returned 13.3% over the past year.

Fiyat Oynaklığı

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	3.1%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: MRK has not had significant price volatility in the past 3 months.

Zaman İçindeki Volatilite: MRK's weekly volatility (3%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1668	62,176	Belen Garijo Lopez	www.merckgroup.com/en

Merck KGaA, Almanya'da bir bilim ve teknoloji şirketi olarak faaliyet göstermektedir. Yaşam Bilimleri, Sağlık Hizmetleri ve Elektronik segmentleri aracılığıyla faaliyet göstermektedir. Şirketin Yaşam Bilimleri segmenti, akademik laboratuvarlar, biyoteknoloji ve ilaç üreticilerinin yanı sıra endüstriyel sektör için araçlar, kimyasallar ve ekipmanlar sunmaktadır.

Merck KGaA Temel Bilgiler Özeti

Merck KGaA'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MRK temel i̇stati̇sti̇kler
Piyasa değeri	€68.00b
Kazançlar(TTM)	€2.63b
Gelir(TTM)	€20.87b

25.9x

F/K Oranı

3.3x

P/S Oranı

MRK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MRK gelir tablosu (TTM)
Gelir	€20.87b
Gelir Maliyeti	€8.68b
Brüt Kâr	€12.19b
Diğer Giderler	€9.57b
Kazançlar	€2.63b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 14, 2024

Hisse başına kazanç (EPS)	6.04
Brüt Marj	58.42%
Net Kâr Marjı	12.58%
Borç/Özkaynak Oranı	35.3%

MRK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.4%

Mevcut Temettü Verimi

36%

Ödeme Oranı

MRK Stoklara Genel Bakış

Ödüller

Risk Analizi

Merck KGaA Rakipler

XTRA:DMP

€1.9b

XTRA:PSG

€251.8m

LSE:GSK

UK£62.1b

TSE:4519

JP¥11.6t

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Recent updates

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Some Confidence Is Lacking In Merck KGaA's (ETR:MRK) P/E

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price

First quarter 2024 earnings: EPS exceeds analyst expectations

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20

Upcoming dividend of €2.20 per share

Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck KGaA (ETR:MRK) Has Affirmed Its Dividend Of €2.20

Dividend of €2.20 announced

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

There's Reason For Concern Over Merck KGaA's (ETR:MRK) Price

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 77% Above Its Share Price

Investor sentiment deteriorates as stock falls 15%

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Does Merck KGaA (ETR:MRK) Have A Healthy Balance Sheet?

Is There An Opportunity With Merck KGaA's (ETR:MRK) 49% Undervaluation?

Second quarter 2023 earnings: Revenues exceed analyst expectations

Merck KGaA, Annual General Meeting, Apr 26, 2024

Is Merck KGaA (ETR:MRK) A Risky Investment?

Are Investors Undervaluing Merck KGaA (ETR:MRK) By 36%?

First quarter 2023 earnings: Revenues in line with analyst expectations

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.3% yield

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Full year 2022 earnings: Revenues in line with analyst expectations

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Third quarter 2022 earnings: Revenues exceed analyst expectations

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of €1.85 per share

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2022 Results on Aug 04, 2022